# Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy

> **NCT02586727** · PHASE2 · COMPLETED · sponsor: **Larkin Community Hospital** · enrollment: 40 (actual)

## Conditions studied

- Adverse Effect of Radiation Therapy

## Interventions

- **DRUG:** aflibercept

## Key facts

- **NCT ID:** NCT02586727
- **Lead sponsor:** Larkin Community Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2018-12
- **Final completion:** 2020-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586727, "Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT02586727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*